nach oben

Drugs

Erschienen in:

01.01.2022 | AdisInsight Report

Atogepant: First Approval

verfasst von: Emma D. Deeks

Erschienen in: Drugs | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Abstract

Atogepant (Qulipta™) is an orally administered, small-molecule, calcitonin gene-related peptide (CGRP) receptor antagonist being developed by AbbVie for the prophylaxis of migraine. In September 2021, atogepant was approved in the USA for the preventive treatment of episodic migraine in adults. The drug is also in phase 3 clinical development for the preventive treatment of migraine in various other countries. This article summarizes the milestones in the development of atogepant leading to this first approval for the preventive treatment of episodic migraine in adults.

Nur mit Berechtigung zugänglich

Eigenbrodt AK, Ashina H, Khan S, et al. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021;17(8):501–14.CrossRef

de Vries T, Villalón CM, MaassenVanDenBrink A. Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans. Pharmacol Ther. 2020;211: 107528. https://doi.org/10.1016/j.pharmthera.2020.107528.CrossRefPubMed

Chan C, Goadsby PJ. Recent advances in pharmacotherapy for episodic migraine. CNS Drugs. 2019;33(11):1053–71.CrossRef

AbbVie. QULIPTA (atogepant) tablets, for oral use: US prescribing information. 2021. https://www.accessdata.fda.gov. Accessed 30 Sept 2021.

AbbVie. FDA approves QULIPTA™ (atogepant), the first and only oral CGRP receptor antagonist specifically developed for the preventive treatment of migraine [media release]. 28 Sept 2021. https://news.abbvie.com.

Allergan and Merck Co. Allergan enters into licensing agreement with Merck to obtain exclusive worldwide rights to CGRP migraine development program [media release]. 7 July 2015. http://www.allergan.com.

Rubio-Beltran E, Chan KY, Danser AJ, et al. Characterisation of the calcitonin gene-related peptide receptor antagonists ubrogepant and atogepant in human isolated coronary, cerebral and middle meningeal arteries. Cephalalgia. 2020;40(4):357–66.CrossRef

Melo-Carrillo A, Strassman AM, Schain AJ, et al. Combined onabotulinumtoxinA/atogepant treatment blocks activation/sensitization of high-threshold and wide-dynamic range neurons. Cephalalgia. 2021;41(1):17–32.CrossRef

Boinpally R, McNamee B, Yao L, et al. A single supratherapeutic dose of atogepant does not affect cardiac repolarization in healthy adults: results from a randomized, single-dose, phase 1 crossover trial. Clin Pharmacol Drug Dev. 2021;10(9):1099–107.CrossRef

10.

Min KC, Kraft WK, Bondiskey P, et al. Atogepant is not associated with clinically meaningful alanine aminotransferase elevations in healthy adults. Clin Transl Sci. 2021;14(2):599–605.CrossRef

11.

Rowe J, Chan H, Chandrasekar P, et al. Mass balance and metabolism of carbon-14 atogepant in healthy male participants [abstract]. Neurology. 2021;96(15 Suppl).

12.

Boinpally R, Jakate A, Butler M, et al. Single-dose pharmacokinetics and safety of atogepant in adults with hepatic impairment: results from an open-label, phase 1 trial. Clin Pharmacol Drug Dev. 2021;10(7):726–33.CrossRef

13.

Boinpally R, Spaventa J, Chen K, et al. Evaluation of the pharmacokinetic interaction and safety of atogepant co-administered with acetaminophen or naproxen in healthy participants: a randomized trial. Clin Drug Investig. 2021;41(6):557–67.CrossRef

14.

Boinpally R, Butler M, Rojo J, et al. Evaluation of the pharmacokinetic interaction and safety of atogepant coadministered with esomeprazole magnesium [abstract no P-127]. Headache. 2021;61(Suppl 1):94–5.

15.

Ankrom W, Xu J, Vallee MH, et al. Atogepant has no clinically relevant effects on the pharmacokinetics of an ethinyl estradiol/levonorgestrel oral contraceptive in healthy female participants. J Clin Pharmacol. 2020;60(9):1157–65.CrossRef

16.

Boinpally R, Jakate A, Butler M, et al. Coadministration of single therapeutic oral doses of atogepant and sumatriptan produces no clinically relevant drug-drug interactions [abstract]. Headache. 2020;60(Suppl 1):35.

17.

Boinpally R, Forsythe C, Borbridge L, et al. Evaluation of pharmacokinetic interactions and safety of atogepant coadministered with quinidine gluconate [abstract]. Neurology. 2021;96(15 Suppl 1).

18.

Ailani J, Lipton RB, Goadsby PJ, et al. Atogepant for the preventive treatment of migraine. N Engl J Med. 2021;385(8):695–706.CrossRef

19.

Schwedt TJ, Lipton RB, Ailani J, et al. Time course of efficacy of atogepant for the preventive treatment of migraine: results from the randomized, double-blind ADVANCE trial. Cephalalgia. 2021. https://doi.org/10.1177/03331024211042385.CrossRefPubMedPubMedCentral

20.

Goadsby PJ, Dodick DW, Ailani J, et al. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial. Lancet Neurol. 2020;19(9):727–37.CrossRef

21.

Ashina M, Tepper SJ, Reuter U, et al. Atogepant 60 mg once-daily shows efficacy for the preventive treatment of migraine: results from a 52-week open- label extension trial [abstract no. P-133]. Headache. 2021;61(Suppl 1).

22.

Lipton RB, Halker Singh RB, Mechtler LL, et al. Daily dosing of atogepant for preventive treatment of migraine improved patient-reported outcomes measures of migraine-specific quality of life, activity impairment in migraine-diary, and headache-impact test in a 52-week trial [abstract no. P-203]. Headache. 2021;61(Suppl 1):119–20.

23.

Ashina M, Tepper S, Reuter U, et al. Long-term safety and tolerability of atogepant 60 mg following once daily dosing over 1 year for the preventive treatment of migraine [abstract]. Neurology. 2021;96(15 Suppl 1).

Titel: Atogepant: First Approval
verfasst von: Emma D. Deeks
Publikationsdatum: 01.01.2022
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 1/2022
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.1007/s40265-021-01644-5

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Atogepant: First Approval

Abstract

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2022

Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Use Associated with Reduced Mortality and Other Disease Outcomes in US Veterans with COVID-19

Correction to: Maralixibat: First Approval

Correction to: Infigratinib: First Approval

Maralixibat: First Approval

Drug Treatment of Cluster Headache

Rationale and Clinical Use of Bronchodilators in Adults with Bronchiectasis